Multiple mechanisms of action of pyridoxine in primary hyperoxaluria type 1.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Biochimica et Biophysica Acta

• Publication date

  2013-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.bbadis.2013.04.010PMID 23597595
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Measurement of plasma B6 vitamer profiles in children with inborn errors of vitamin B6 metabolism using an LC-MS/MS method

  2013cited by this paper
• Four of the Most Common Mutations in Primary Hyperoxaluria Type 1 Unmask the Cryptic Mitochondrial Targeting Sequence of Alanine:glyoxylate Aminotransferase Encoded by the Polymorphic Minor Allele*

  2012cited by this paper
• Primary hyperoxaluria type 1, a too often missed diagnosis and potentially treatable cause of end-stage renal disease in adults: results of the Dutch cohort.

  2012cited by this paper
• α-Galactosidase Aggregation Is a Determinant of Pharmacological Chaperone Efficacy on Fabry Disease Mutants*

  2012cited by this paper
• The N-terminal extension is essential for the formation of the active dimeric structure of liver peroxisomal alanine:glyoxylate aminotransferase.

  2012cited by this paper
• Pyridoxal 5'-phosphate in cerebrospinal fluid; factors affecting concentration

  2011cited by this paper
• Molecular defects of the glycine 41 variants of alanine glyoxylate aminotransferase associated with primary hyperoxaluria type I

  2010cited by this paper
• Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome.

  2010cited by this paper
• Molecular Insight into the Synergism between the Minor Allele of Human Liver Peroxisomal Alanine:Glyoxylate Aminotransferase and the F152I Mutation*

  2009cited by this paper
• Partial trypsin digestion as an indicator of mis-folding of mutant alanine:glyoxylate aminotransferase and chaperone effects of specific ligands. Study of a spectrum of missense mutants.

  2008cited by this paper
• Mutation-based diagnostic testing for primary hyperoxaluria type 1: survey of results.

  2008cited by this paper
• In Vivo and in Vitro Examination of Stability of Primary Hyperoxaluria-associated Human Alanine:Glyoxylate Aminotransferase*

  2008cited by this paper
• Selected exonic sequencing of the AGXT gene provides a genetic diagnosis in 50% of patients with primary hyperoxaluria type 1.

  2007cited by this paper
• A guided tour into subcellular colocalization analysis in light microscopy

  2006cited by this paper
• Reconstruction of human hepatocyte glyoxylate metabolic pathways in stably transformed Chinese-hamster ovary cells.

  2006cited by this paper
• B6-responsive disorders: A model of vitamin dependency

  2006cited by this paper
• Consequences of missense mutations for dimerization and turnover of alanine:glyoxylate aminotransferase: study of a spectrum of mutations.

  2006cited by this paper
• Multianalyte quantification of vitamin B6 and B2 species in the nanomolar range in human plasma by liquid chromatography-tandem mass spectrometry.

  2005cited by this paper
• Implications of Genotype and Enzyme Phenotype in Pyridoxine Response of Patients with Type I Primary Hyperoxaluria

  2005cited by this paper
• Overexpression of human alanine:glyoxylate aminotransferase in Escherichia coli: renaturation from guanidine-HCl and affinity for pyridoxal phosphate co-factor.

  2005cited by this paper
• Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele.

  2005cited by this paper
• Effects of oral pyridoxine upon plasma and 24-hour urinary oxalate levels in normal subjects and stone formers with idiopathic hypercalciuria

  2004cited by this paper
• Clinical implications of mutation analysis in primary hyperoxaluria type 1.

  2004cited by this paper
• Plasma vitamin B6 vitamers before and after oral vitamin B6 treatment: a randomized placebo-controlled study.

  2003cited by this paper
• Correction of an enzyme trafficking defect in hereditary kidney stone disease in vitro.

  2003cited by this paper
• A United States survey on diagnosis, treatment, and outcome of primary hyperoxaluria

  2003cited by this paper
• Primary hyperoxaluria type 1 in the Canary Islands: A conformational disease due to I244T mutation in the P11L-containing alanine:glyoxylate aminotransferase

  2003cited by this paper
• The peroxisomal targeting sequence type 1 receptor, Pex5p, and the peroxisomal import efficiency of alanine:glyoxylate aminotransferase.

  2000cited by this paper
• Functional Synergism between the Most Common Polymorphism in Human Alanine:Glyoxylate Aminotransferase and Four of the Most Common Disease-causing Mutations*

  2000cited by this paper
• Effect of N-terminal α-Helix Formation on the Dimerization and Intracellular Targeting of Alanine:Glyoxylate Aminotransferase*

  1999cited by this paper
• Pyridoxine refractory X-linked sideroblastic anemia caused by a point mutation in the erythroid 5-aminolevulinate synthase gene.

  1997cited by this paper
• Degradation of tyrosine aminotransferase (TAT) via the ubiquitin–proteasome pathway

  1997cited by this paper
• A Semiautomated Alanine: Glyoxylate Aminotransferase Assay for the Tissue Diagnosis of Primary Hyperoxaluria Type 1

  1997cited by this paper
• Late-onset X-linked sideroblastic anemia. Missense mutations in the erythroid delta-aminolevulinate synthase (ALAS2) gene in two pyridoxine-responsive patients initially diagnosed with acquired refractory anemia and ringed sideroblasts.

  1995cited by this paper
• Changing pattern of primary hyperoxaluria in Switzerland.

  1995cited by this paper
• Enzymological and mutational analysis of a complex primary hyperoxaluria type 1 phenotype involving alanine:glyoxylate aminotransferase peroxisome-to-mitochondrion mistargeting and intraperoxisomal aggregation.

  1993cited by this paper
• Primary hyperoxaluria type 1 and peroxisome-to-mitochondrion mistargeting of alanine:glyoxylate aminotransferase.

  1993cited by this paper
• Liquid chromatographic studies of vitamin B6 metabolism in man.

  1990cited by this paper
• Identification of mutations associated with peroxisome-to-mitochondrion mistargeting of alanine/glyoxylate aminotransferase in primary hyperoxaluria type 1

  1990cited by this paper
• An enzyme trafficking defect in two patients with primary hyperoxaluria type 1: peroxisomal alanine/glyoxylate aminotransferase rerouted to mitochondria

  1989cited by this paper
• Pyridoxine effects on ornithine ketoacid transaminase activity in fibroblasts from carriers of two forms of gyrate atrophy of the choroid and retina.

  1988cited by this paper
• Molecular basis of ornithine aminotransferase deficiency in B-6-responsive and -nonresponsive forms of gyrate atrophy.

  1988cited by this paper
• Peroxisomal alanine:glyoxylate aminotransferase deficiency in primary hyperoxaluria type I

  1986cited by this paper
• Plasma content of B6 vitamers and its relationship to hepatic vitamin B6 metabolism.

  1980cited by this paper
• Gyrate atrophy of the choroid and retina with hyperornithinemia: biochemical and histologic studies and response to vitamin B6.

  1980cited by this paper
• Studies on some possible biochemical treatments of primary hyperoxaluria.

  1979cited by this paper
• delta-Aminolevulinic acid synthetase in erythroblasts of patients with pyridoxine-responsive anemia. Hypercatabolism caused by the increased susceptibility to the controlling protease.

  1979cited by this paper
• Vitamin B6 in management of gyrate atrophy of choroid and retina.

  1978cited by this paper
• Letter: Traumatic encephalopathy in a young boxer.

  1974cited by this paper
• The action of pyridoxine in primary hyperoxaluria.

  1970cited by this paper
• THE COFACTOR-MEDIATED REGULATION OF APOENZYME LEVELS IN ANIMAL TISSUES. I. THE PYRIDOXINE-INDUCED RISE OF RAT LIVER TYROSINE TRANSAMINASE LEVEL IN VIVO.

  1963cited by this paper

• Genetic Insights Into Nephrolithiasis and Renal Cancer Predisposition: Precision Medicine in Genes, Diagnosis, and Therapy.

  2025cites this paper
• Clinical characteristics of Russian children with primary hyperoxaluria. Results of a pilot study of lumasiran therapy of primary hyperoxaluria type 1

  2025cites this paper
• Primary Hyperoxaluria Type 1: An Unexpected Diagnosis after Kidney Transplantation

  2025cites this paper
• Effectiveness of RNA interference therapies in reducing urine and plasma oxalate levels among patients with primary hyperoxaluria- A systematic review

  2025cites this paper
• Preclinical evaluation of AGT mRNA replacement therapy for primary hyperoxaluria type I disease

  2025cites this paper
• Nanobodies as therapies for loss-of-function misfolding diseases

  2025cites this paper
• Nonpharmacologic Methods of Stone Risk Reduction: Diet and Supplements.

  2025cites this paper
• Functional analysis of amino acid substitutions within human AGT1 in a cell-based platform to support the diagnosis of primary hyperoxaluria type 1

  2025cites this paper
• Navigating the Evolving Landscape of Primary Hyperoxaluria: Traditional Management Defied by the Rise of Novel Molecular Drugs

  2024cites this paper
• Lipid nanoparticle-mediated base-editing of the Hao1 gene achieves sustainable primary hyperoxaluria type 1 therapy in rats

  2024cites this paper
• Extending diagnostic practices in gyrate atrophy: Enzymatic characterization and the development of an in vitro pyridoxine responsiveness assay.

  2024cites this paper
• Oxalates: Dietary Oxalates and Kidney Inflammation: A Literature Review.

  2024cites this paper
• Recovery From Severe Heart Failure in a Patient With Primary Hyperoxaluria Type 1 After Treatment With Lumasiran, Pyridoxine, and Kidney Transplant

  2024cites this paper
• Diagnosis and management of primary hyperoxalurias: best practices

  2024influential citation
• Review of childhood genetic nephrolithiasis and nephrocalcinosis

  2024cites this paper
• Effect of the allelic background on the phenotype of primary hyperoxaluria type I

  2024cites this paper
• Natural history of urine and plasma oxalate in children with primary hyperoxaluria type 1

  2023cites this paper
• Medical management of urolithiasis: Great efforts and limited progress

  2023cites this paper
• Stiripentol and Lumasiran as a Rescue Therapy for Oxalate Nephropathy Recurrence After Kidney Transplantation in an Adult Patient With Primary Hyperoxaluria Type 1.

  2023cites this paper
• Biochemical and cellular effects of a novel missense mutation of the AGXT gene associated with Primary Hyperoxaluria Type 1.

  2023cites this paper
• Determinants of Kidney Failure in Primary Hyperoxaluria Type 1: Findings of the European Hyperoxaluria Consortium

  2023influential citation
• Multiplex gene editing reduces oxalate production in primary hyperoxaluria type 1

  2023cites this paper
• Genetic assessment in primary hyperoxaluria: why it matters

  2022influential citation
• Nephrolithiasis: Insights into Biomimics, Pathogenesis, and Pharmacology

  2022cites this paper
• Chitosan Derivatives as Nanocarriers for hLDHA Inhibitors Delivery to Hepatic Cells: A Selective Strategy for Targeting Primary Hyperoxaluria Diseases.

  2022cites this paper
• Clinical and molecular characterization of primary hyperoxaluria in Egypt

  2022cites this paper
• CRISPR/Cas9-mediated knock-out of AGXT1 in HepG2 cells as a new in vitro model of Primary Hyperoxaluria Type 1.

  2022cites this paper
• Lumasiran in the Management of Patients with Primary Hyperoxaluria Type 1: From Bench to Bedside

  2022cites this paper
• Primary hyperoxaluria type 1: pathophysiology and genetics

  2022cites this paper
• Treatment of primary hyperoxaluria type 1

  2022cites this paper
• New salicylic acid derivatives, double inhibitors of glycolate oxidase and lactate dehydrogenase, as effective agents decreasing oxalate production.

  2022cites this paper
• Improved Outcome of Infantile Oxalosis Over Time in Europe: Data From the OxalEurope Registry

  2022cites this paper
• A novel nonsense variant of the AGXT identified in a Chinese family: special variant research in the Chinese reference genome

  2021cites this paper
• Long-Term Transplantation Outcomes in Patients With Primary Hyperoxaluria Type 1 Included in the European Hyperoxaluria Consortium (OxalEurope) Registry

  2021cites this paper
• Dimerization Drives Proper Folding of Human Alanine:Glyoxylate Aminotransferase But Is Dispensable for Peroxisomal Targeting

  2021cites this paper
• Perspectives in primary hyperoxaluria — historical, current and future clinical interventions

  2021cites this paper
• Therapeutic RNA interference: A novel approach to the treatment of primary hyperoxaluria

  2021cites this paper
• Medical management for the prevention of kidney stones

  2021cites this paper
• Lumasiran: expanding the treatment options for patients with primary hyperoxaluria type 1

  2021influential citation
• Endogenous Oxalate Production in Primary Hyperoxaluria Type 1 Patients

  2021cites this paper
• Primary Hyperoxaluria Type 1 (PH1) Presenting With End-Stage Kidney Disease and Cutaneous Manifestations in Adulthood: A Case Report

  2021cites this paper
• Importance of Assessing Compliance with Conservative Treatment of Primary Hyperoxaluria Type 1: A Case Report of a Patient with I244T/c.969-3C>G Mutation.

  2020cites this paper
• The Metabolic Importance of the Overlooked Asparaginase II Pathway.

  2020cites this paper
• Vitamin B6-dependent enzymes and disease

  2020cites this paper
• Pyridoxine Responsiveness in a Type 1 Primary Hyperoxaluria Patient With a Rare (Atypical) AGXT Gene Mutation

  2020cites this paper
• Transplantation for Primary Hyperoxaluria Type 1: Designing New Strategies in the Era of Promising Therapeutic Perspectives

  2020cites this paper
• Investigational therapies for primary hyperoxaluria.

  2020cites this paper
• The ILE56 mutation on different genetic backgrounds of alanine: Glyoxylate aminotransferase: Clinical features and biochemical characterization.

  2020cites this paper
• Recovery From Dialysis in Patients With Primary Hyperoxaluria Type 1 Treated With Pyridoxine: A Report of 3 Cases.

  2020cites this paper
• Effect of Alanine Supplementation on Oxalate Synthesis.

  2020cites this paper
• Endpoints for Clinical Trials in Primary Hyperoxaluria.

  2020cites this paper
• Structural and functional insights on the roles of molecular chaperones in the mistargeting and aggregation phenotypes associated with primary hyperoxaluria type I.

  2019cites this paper
• The Effect of Calcium and Vitamin B6 Supplementation on Oxalate Excretion in a Rodent Gastric Bypass Model of Enteric Hyperoxaluria.

  2019cites this paper
• From pathogenesis to novel therapies in primary hyperoxaluria

  2019cites this paper
• Nephrolithiasis.

  2019cites this paper
• Hyperoxalurie

  2019cites this paper
• Consciousness Energy Healing Treatment: Impact on the Physicochemical and Thermal Properties of Pyridoxine HCl

  2019cites this paper
• Recent advances in the identification and management of inherited hyperoxalurias

  2018cites this paper
• Targeting Trafficking in Drug Development

  2018cites this paper
• Folding Defects Leading to Primary Hyperoxaluria.

  2018cites this paper
• Updated Genetic Testing of Primary Hyperoxaluria Type 1 in a Chinese Population: Results from a Single Center Study and a Systematic Review

  2018cites this paper
• Molecular and cellular basis of ornithine δ-aminotransferase deficiency caused by the V332M mutation associated with gyrate atrophy of the choroid and retina.

  2018cites this paper
• A non-resolving skin lesion in hemodialysis patient: Answers

  2018cites this paper
• Salicylic Acid Derivatives Inhibit Oxalate Production in Mouse Hepatocytes with Primary Hyperoxaluria Type 1.

  2018cites this paper
• Estudo do teor de ácido oxálico em hortaliças e frutos, seu potencial de cristalização in vitro e caracterização morfológica de cristais de oxalato de cálcio

  2018cites this paper
• Development of advanced genetic therapies for primary hyperoxaluria tipe I

  2018cites this paper
• Renal transplantation and rare diseases

  2018cites this paper
• Protein misfolding diseases: Prospects of pharmacological treatment

  2018influential citation
• Primary hyperoxaluria type 1: a case report in a 7-month-old Chinese infant under biopsy and light microscope diagnosis

  2018cites this paper
• Transfert de gènes dans les cellules souches pluripotentes induites : application à la thérapie génique de l'hyperoxalurie primitive de type 1

  2018cites this paper
• Metaphylaxis in Pediatric Urinary Stone Disease

  2017cites this paper
• Electrostatic interactions drive native‐like aggregation of human alanine:glyoxylate aminostransferase

  2017cites this paper
• Drug Library Screening for the Identification of Ionophores That Correct the Mistrafficking Disorder Associated with Oxalosis Kidney Disease

  2017cites this paper
• Use of polymer conjugates for the intraperoxisomal delivery of engineered human alanine:glyoxylate aminotransferase as a protein therapy for primary hyperoxaluria type I.

  2017cites this paper
• Treatment options in primary hyperoxaluria Type I

  2017cites this paper
• L’hyperoxalurie primitive, aujourd’hui et demain

  2017cites this paper
• GC-MS INVESTIGATION OF METABOLIC ACTIVITY IN 4-HYDROXY-2-OXOGLUTARATE ALDOLASE DEFICIENCY OF PRIMARY HYPEROXALURIA TYPE 3 BY JORDAN

  2016cites this paper
• Two novel AGXT mutations identified in primary hyperoxaluria type-1 and distinct morphological and structural difference in kidney stones

  2016cites this paper
• Natural and Unnatural Compounds Rescue Folding Defects of Human Alanine: Glyoxylate Aminotransferase Leading to Primary Hyperoxaluria Type I.

  2016cites this paper
• Predictors of Incident ESRD among Patients with Primary Hyperoxaluria Presenting Prior to Kidney Failure.

  2016cites this paper
• Primary Hyperoaxaluria in Children

  2016cites this paper
• High throughput cell-based assay for identification of glycolate oxidase inhibitors as a potential treatment for Primary Hyperoxaluria Type 1

  2016cites this paper
• Effects of alanine:glyoxylate aminotransferase variants and pyridoxine sensitivity on oxalate metabolism in a cell-based cytotoxicity assay.

  2016influential citation
• Assessment of Urine Proteomics in Type 1 Primary Hyperoxaluria

  2016cites this paper
• The Chaperoning Activity of Amino-oxyacetic Acid on Folding-Defective Variants of Human Alanine:Glyoxylate Aminotransferase Causing Primary Hyperoxaluria Type I.

  2015cites this paper
• Development of a Phenotypic High-Content Assay to Identify Pharmacoperone Drugs for the Treatment of Primary Hyperoxaluria Type 1 by High-Throughput Screening

  2015cites this paper
• Molecular basis of primary hyperoxaluria and strategies for diagnosis

  2015cites this paper
• Primary Hyperoxaluria in Children

  2015cites this paper
• Proline dehydrogenase 2 (PRODH2) is a hydroxyproline dehydrogenase (HYPDH) and molecular target for treating primary hyperoxaluria.

  2015cites this paper
• SNP Variants in RET and PAX2 and Their Possible Contribution to the Primary Hyperoxaluria Type 1 Phenotype

  2015cites this paper
• Misfolding caused by the pathogenic mutation G47R on the minor allele of alanine:glyoxylate aminotransferase and chaperoning activity of pyridoxine.

  2015cites this paper
• Pyridoxamine and pyridoxal are more effective than pyridoxine in rescuing folding-defective variants of human alanine:glyoxylate aminotransferase causing primary hyperoxaluria type I.

  2015cites this paper
• Molecular Recognition of PTS-1 Cargo Proteins by Pex5p: Implications for Protein Mistargeting in Primary Hyperoxaluria

  2015cites this paper
• SNP Variants in RET and PAX 2 and Their Possible Contribution to the Primary Hyperoxaluria Type 1 Phenotype

  2015cites this paper
• Engineering a pyridoxal 5’-phosphate supply for cadaverine production by using Escherichia coli whole-cell biocatalysis

  2015cites this paper
• Primary hyperoxalurias: diagnosis and treatment

  2015cites this paper
• Phenotype-Genotype Correlations and Estimated Carrier Frequencies of Primary Hyperoxaluria.

  2015cites this paper
• Sustained Pyridoxine Response in Primary Hyperoxaluria Type 1 Recipients of Kidney Alone Transplant

  2014cites this paper
• Full Review Protein traf fi cking defects in inherited kidney diseases

  2014cites this paper
• Protein trafficking defects in inherited kidney diseases.

  2014cites this paper